Advanced searches left 3/3

CELL Function - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 May 2022

* If you want to update the article please login/register

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)

Adults with T2DM of 7 years on 0-2 anti-diabetic drugs, including glargine and pre-meal insulin lispro will be randomized to 8 weeks of therapy with either basal insulin glargine, intensive insulin therapy consisting of glargine and pre-meal insulin lispro, or glargine and the GLP-1 agonist exenatide.

Source link: https://clinicaltrials.gov/ct2/show/NCT02194595


A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.

Patients will be randomized to either oral ladarixin therapy or placebo. Both Ladarixin and placebo will be administered for 1 year. From the 1st administration of the study drugs, all patients will be followed-up for 18 months. When the last patient randomized has completed the month 12 follow-up visit, the research database will be locked and results will be analyzed.

Source link: https://clinicaltrials.gov/ct2/show/NCT04899271


Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With New-onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY)

It has been developed to investigate whether ladarixin is safe in preserving beta-cell function and slowing-down the development of T1D in patients with a more severe disease course. The Principal Investigator PI, the protocol, GCP guidelines, and local rules would all be responsible for ensuring that the investigation is carried out according to the signed Investigator deal, the protocol, GCP guidelines, and local policies. For 13 cycles of 14 days on/14 days off, placebo control group or matched placebo control group, a treatment group or matched placebo control group was compared.

Source link: https://clinicaltrials.gov/ct2/show/NCT04628481

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions